References
- Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL et al. (2007). Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol, 34:415–423.
- Park JH, Saravanakumar G, Kim K, Kwon IC. (2010). Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev, 62:28–41.
- Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. (2000). Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res, 60:3389–3393.
- Barreiro-Iglesias R, Bromberg L, Temchenko M, Hatton TA, Concheiro A, Alvarez-Lorenzo C. (2004). Solubilization and stabilization of camptothecin in micellar solutions of pluronic-g-poly(acrylic acid) copolymers. J Control Release, 97:537–549.
- Jang JH, Kim CK, Choi HG, Sung JH. (2009). Preparation and evaluation of 2-(allylthio)pyrazine-loaded lipid emulsion with enhanced stability and liver targeting. Drug Dev Ind Pharm, 35:363–368.
- Lin A, Chen J, Liu Y, Deng S, Wu Z, Huang Y et al. (2009). Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting. Drug Dev Ind Pharm, 35:1348–1355.
- Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. (2007). Characterization of nanoparticles for therapeutics. Nanomedicine (Lond), 2:789–803.
- De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. (2008). Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials, 29:1912–1919.
- Alexis F, Pridgen E, Molnar LK, Farokhzad OC. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm, 5:505–515.
- Kutscher HL, Chao P, Deshmukh M, Sundara Rajan S, Singh Y, Hu P et al. (2010). Enhanced passive pulmonary targeting and retention of PEGylated rigid microparticles in rats. Int J Pharm, 402:64–71.
- Calvo P, Gouritin B, Chacun H, Desmaële D, D’Angelo J, Noel JP et al. (2001). Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res, 18:1157–1166.
- Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. (2003). Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev, 55:519–548.
- Stella VJ, Rajewski RA. (1997). Cyclodextrins: Their future in drug formulation and delivery. Pharm Res, 14:556–567.
- Bibby DC, Davies NM, Tucker IG. (2000). Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm, 197:1–11.
- Leroy-Lechat F, Wouessidjewe D, Andreux JP, Puisieux F, Duchêne, D. (1994). Evaluation of the toxicity of cyclodextrins and hydroxypropylated derivatives. Int J Pharm, 101:97–103.
- Li SD, Huang L. (2008). Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm, 5:496–504.
- Tong W, Wang L, D’Souza MJ. (2003). Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin. Drug Dev Ind Pharm, 29:745–756.
- Mu L, Elbayoumi TA, Torchilin VP. (2005). Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int J Pharm, 306:142–149.
- Duchêne D, Ponchel G, Wouessidjewe D. (1999). Cyclodextrins in targeting. Application to nanoparticles. Adv Drug Deliv Rev, 36:29–40.
- Schoemaker NE, Frigerio E, Fraier D, Schellens JH, Rosing H, Jansen S et al. (2001). High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma. J Chromatogr B Biomed Sci Appl, 763:173–183.
- Yang L, Cui F, Cun D, Tao A, Shi K, Lin W. (2007). Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int J Pharm, 340:163–172.
- Nishikawa M, Takakura Y, Hashida M. (2005). Theoretical considerations involving the pharmacokinetics of plasmid DNA. Adv Drug Deliv Rev, 57:675–688.
- Li L, Wei P, Liu J. (2009). [Study on pharmacokinetics model for targeted drug delivery systems]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, 26:526–529.